Serum survivin and TP53 gene expression in children with acute lymphoblastic leukemia

Iranian Journal of Public Health

Volumn 41, Issue 1, 2012, Pages 37-44

  Yahya, Raida S ^a   Fouda, Manal I ^b   El Baz, Hatim A ^c   Mosa, Tamer E ^c   Abd Elmaksoud, Mohamed D ^c  

^a MANSOURA UNIVERSITY CHILDREN S HOSPITAL   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Acute lymphoblastic leukemia; ELISA; Flow cytometry; Gene expression; P53; Survivin

Indexed keywords

EID: 84856578398     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Harrison CJ (2001). Acute lymphoblastic leukaemia. Best Pract ResCl Ha, 14:593-607.
2. Ribera JM, Oriol A (2009). Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am, 23(5):1033-42.
3. Fridman JS, Lowe SW(2003). Control of apoptosis by p53. Oncogene, 22: 9030-40.
4. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al (2003). Caspasemediated cleavage converts livin froman antiapoptotic to a pro-apoptotic factor: implica tions for drug-resistant melanoma. Cancer Res, 63:6340-9.
5. Arrends MJ, Willie AH (1991). Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol, 32:223-4.
6. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science, 252(5013):1708-11.
7. Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408:307-10.
8. Bode AM, Dong Z (2004). Post-translational modification of p53 in tumorigenesis. Nat RevCancer, 4:793-805.
9. National Center for Biotechnology Information (2008). The p53 tumor suppressor protein. Genes and Disease. United States National Institutes ofHealth.Retrieved -05-28.
10. Hengartner MO (2000). The biochemistry of apoptosis. Nature, 407:770-6.
11. Altieri DC (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. TrendsMolMed, 7:542-7.
12. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW(2002). DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther, 303(1):124-31.
13. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, et al (2006). KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem, 281(21):14711-8.
14. Schabath R, Ratei R, Ludwig W (2003). The prognostic significance of antigen expression in leukaemia. Best Pract Res Cl Ha, 16(4):613-28.
15. Goyal L (2001). Cell death inhibition: keeping caspases in check. Cell, 104:805-8.
16. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM (2007). Survivin: a promising tumor biomarker. Cancer Lett, 249:49-60.
17. Fan J, Wang L, Jiang GN, He WX, Ding JA (2008). The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer, 61:91-6.
18. Karanikas V, Tsohas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J, et al (2008). Coexpression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther, 7:345-52.
19. Altieri DC (2003). Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res, 5:447-52.
20. Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. NatMed, 3:917-21
21. Tracey L, Pérez-Rosado A, Artiga MJ et al. (2005). Expression of the NF KB targets BCL2 and BIRC5/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol, 206:123-34.
22. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, et al (2004). Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia, 18:616-23.
23. Carter BZ, Mak DH, Schober WD et al. (2006). Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood, 107:1555-63.
24. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004). Survivin expression predicts poorer prognosis in anaplastic largecell lymphoma. J Clin Oncol, 22:1682-8.
25. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al (2000). Prognostic significance of survivin expression in diffuse largeB-cell lymphomas. Blood, 96:1921-5.
26. Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel U (2007). Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk Res, 31(11):1495-501.
27. Zolota V, Siriniana C, Melachrinoua M, Symeonidisb A, Bonikosa D (2007). Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53,mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival. Pathol Res Pract, 203:199-207.
28. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S (2000). Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol, 102:115-23.
29. Gustafsson B, Christenson B, Hjalmar V, Winiarski J (2000). Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol, 34(2):117-24.
30. Haupt Y, Maya R, Kazaz A, Oren M (1997). Mdm2 promote the rapid degradation of p53. Nature, 387:296-9.
31. Collot-Teixeira S, Bass J, Denis F, Ranger- Rogez S (2004). Human tumor suppressor p53 and DNA viruses. Rev Med Virol, 14:301-19.
32. Abdelmoula-Souissi S, Rekik L, Gargouri A, Mokdad-Gargouri R (2007). High-level expression of human tumour suppressor P53 in the methylotrophic yeast: Pichia pastoris. Protein Expres Purif, 54:283-8.
33. Maestro R, Dolcetti R, Gasparotto D et al. (1992). High frequency of P53 gene alteration associated with protein expression in human squamous cell carcinoma of the larynx. Oncogene, 7(6):1159-66.
34. Somers KD, Merrick A, Lopez ME et al. (1992). Frequent P53 mutations in head and neck cancer. CancerRes, 52(21):5997-6000.
35. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J, Pavelic K (2005). Expression of c-myc, erbB-2, p53 and nm23- H1 gene product in benign and malignant breast lesions: Coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol, 79:42-50.
36. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D (1988). P53 expression in breast cancer. Int J Cancer, 41:178-83.
37. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR (1991). Genetic basis for p53 overexpression in human breast cancer. Proc NatlAcad SciUSA, 88:5006-10.
38. Irish J, Anensen N, Hovland R, Skavland J, Børresen-Dale A, Bruserud O, et al (2007). Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood, 109(6):2589-96.
39. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). P53 mutations in human cancers. Science, 253:49-53.
40. Diccianni M, Yu J, Hsiao M, Mukherjee S, Shao L, Yu A (1994). Clinical significance of P53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood, 84(9):3105-12.
41. Bykov VJ, Wiman KG (2003). Novel cancer therapy by reactivation of the P53 apoptosis pathway. AnnMed, 35:458-65.
42. Roth JA, Grammer SF (2004). Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin North Am, 18:215-29.
43. Wright CW, Duckett CS (2005). Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest, 115:2673-8.
44. Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, et al (2004). Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J ExpMed, 199:399-410.
45. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, et al (2000). Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem, 275(13):9102-5.
46. Hui W, Zan Y, Wang X, Kang H, Guan H, Ma X (2008). Expression of Survivin, p53 and its relationship with apoptosis, proliferation in hepatocellular carcinoma(HCC). Journal of NanjingMedical University, 22(4):255-9.
47. Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K (2009). Significance of Pglycoprotein, P53, and survivin expression in renal cell carcinoma. Urol Oncol, (Epub ahead of print)
48. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21(17):2613-22.